Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Research & Development: 2022-2025

Historic Research & Development for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $38.4 million.

  • Entrada Therapeutics' Research & Development rose 22.73% to $38.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.7 million, marking a year-over-year increase of 17.91%. This contributed to the annual value of $125.3 million for FY2024, which is 25.45% up from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Research & Development is $38.4 million, which was up 1.28% from $37.9 million recorded in Q2 2025.
  • Entrada Therapeutics' Research & Development's 5-year high stood at $38.4 million during Q3 2025, with a 5-year trough of $15.7 million in Q4 2022.
  • In the last 3 years, Entrada Therapeutics' Research & Development had a median value of $31.3 million in 2024 and averaged $30.3 million.
  • Data for Entrada Therapeutics' Research & Development shows a peak YoY soared of 80.37% (in 2023) over the last 5 years.
  • Entrada Therapeutics' Research & Development (Quarterly) stood at $15.7 million in 2022, then skyrocketed by 80.37% to $28.3 million in 2023, then increased by 18.08% to $33.4 million in 2024, then climbed by 22.73% to $38.4 million in 2025.
  • Its Research & Development stands at $38.4 million for Q3 2025, versus $37.9 million for Q2 2025 and $32.1 million for Q1 2025.